Faculty, Staff and Student Publications
Language
English
Publication Date
4-1-2026
Journal
European Journal of Nuclear Medicine and Molecular Imaging
DOI
10.1007/s00259-025-07595-3
PMID
41251745
PMCID
PMC13013147
PubMedCentral® Posted Date
11-18-2025
PubMedCentral® Full Text Version
Post-print
Abstract
Purpose: Inhibitors of poly(ADP-ribose) polymerase (PARP), an enzyme with numerous roles in DNA damage response signaling, represent a class of anti-cancer drugs approved for treating solid tumors with defects in the DNA damage response. However, additional methods for identifying patients who would benefit from the use of PARP inhibitors are urgently needed. We evaluated a novel radiotracer, 18F-FluorThanatrace ([18F]-FTT), to noninvasively assess PARP activity with PET/CT before treatment and determine associations between uptake, tumor mutation status, and prior receipt of therapy including PARP inhibitors.
Methods: Fifty-two patients with solid tumors underwent whole-body (skull base to thigh) [18F]-FTT PET/CT scans before beginning PARP inhibitor treatment. The maximum standardized uptake value (SUVmax) was recorded for up to five lesions per patient. All recorded lesions were included in the analysis.
Results: Uptake of [18F]-FTT was confirmed in all 52 patients regardless of primary tumor type (20 breast, 12 ovarian, 7 prostate, 3 pancreas, and 10 other). Lesion-by-lesion analysis revealed significant differences in [18F]-FTT uptake by primary tumor type (P < 0.001) and higher uptake in lesions with BRCA2 mutations (n = 65) than in lesions with other genetic mutations (n = 26) (6.7 vs. 5.5, P = 0.03). Prior receipt of PARP inhibitor was associated with lower SUVmax (4.7 vs. 6.4, P = 0.001), and prior receipt of systemic therapy was also associated with lower SUVmax (4.0 vs. 6.0, P = 0.01).
Conclusions: [18F]-FTT PET/CT may be useful as a noninvasive quantitative assessment of PARP1 enzyme activity in patients with solid tumors; uptake of [18F]-FTT varies based on tumor mutational status and receipt of prior PARP inhihbitor therapy and/or systemic therapy.
Keywords
Humans, Neoplasms, Male, Female, Mutation, Middle Aged, Positron Emission Tomography Computed Tomography, Aged, DNA Damage, Poly (ADP-Ribose) Polymerase-1, Adult, Poly(ADP-ribose) Polymerase Inhibitors, Aged, 80 and over, Fluorine Radioisotopes, [18F]FluorThanatrace, FTT, PARP inhibitors, BRCA, PET imaging biomarker
Published Open-Access
yes
Recommended Citation
Daoud, Tarek; Chen, Jiansong; Wei, Peng; et al., "Baseline PARP-1 PET Imaging in Patients With Advanced Solid Tumors With DNA Damage Response Mutations" (2026). Faculty, Staff and Student Publications. 6779.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/6779
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons